7月11日，AH股创新药板块齐走高，A股药明康德涨停，常山药业涨超15%，港股药明康德、药明 合联均涨超10%。截至发稿，A股医药生物板块主力资金净流入超55亿元，其中，药明康德主力净 流入超10亿元，常山药业主力净流入超5亿元。 2025.07. 11 本文字数：527，阅读时长大约1分钟 作者 | 一财资讯 招银国际认为，短期来看，创新药估值受市场对出海交易预期影响而攀升，但需理性看待其股价上升 空间。创新药行业具有高风险、长周期、高回报的特征，出海交易的达成往往需要较长时间的研发积 累。 微信编辑 | 七三 推荐阅读 "黄金平替"，单日大跌6%！ 消息面上，7月以来，创新药板块频频迎来政策利好。昨日，国家医保局公布《2025年国家基本医 疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》，明确2025年 基本医保药品目录调整和商业健康保险创新药品目录制定将同步进行。而在1日，重磅政策《支持创 新药高质量发展的若干措施》印发。 中金公司表示，创新药产业投资趋势明确，向上传导或有产业链机会。长期看，中国创新药已进入渐 进式创新时代，开始具备国际竞争力；中期看，具备竞争力的临床数据和M ...

Group 1: Market Performance - The biopharmaceutical, innovative drug, and pharmaceutical outsourcing sectors are experiencing strong performance, with WuXi AppTec rising over 9% and WuXi Biologics also increasing by over 9%, contributing to a 1.5% rise in the Hang Seng Biotechnology Index [1] - The Hang Seng Medical ETF (513060) opened high and fluctuated throughout the morning, nearing a 1% increase with a trading volume of nearly 1 billion yuan, indicating active trading [1] Group 2: Policy and Industry Growth - In the first half of 2025, China's innovative medical device sector achieved a milestone with 45 innovative medical devices approved for market, a year-on-year increase of 87%, marking the highest growth rate in history [2] - The approval of innovative drugs also saw a significant increase, with 43 new drugs approved, reflecting a 59% year-on-year growth, driven by ten regulatory optimization measures from the National Medical Products Administration [2] Group 3: Domestic Innovations - The approved innovative medical devices exhibit characteristics of high-end, precision, and platform-based technologies, achieving significant breakthroughs in three areas: precision intervention, structural heart disease, and energy ablation [3] - The domestic IVUS catheter has broken the monopoly of international giants, receiving EU certification and entering the European market, showcasing China's capability in high-end interventional devices [3] - The domestic transcatheter tricuspid valve repair system is the first of its kind approved in China, addressing a significant clinical need for over 1 million patients with severe tricuspid regurgitation [3] Group 4: Robotics and AI Integration - The integration of medical robotics and artificial intelligence is transforming clinical operations, with domestic surgical robots successfully performing complex minimally invasive surgeries [4] - A new business model combining "robot leasing + industry platform" is emerging to lower the cost barriers for hospitals, facilitating the adoption of advanced robotic technologies [4] Group 5: Future Outlook - The combination of AI models and robotic technology is expected to reshape the entire chain from auxiliary diagnosis to surgical execution, with regulatory bodies accelerating clinical transitions [5] - The Hang Seng Medical ETF (513060) is positioned to benefit from the robust growth of the medical device industry, supported by favorable policies and increasing demand due to an aging population [6][7]

Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) increased by 1.64% as of July 11, 2025, with notable gains from companies like WuXi AppTec (up 9.84%) and Sihuan Pharmaceutical (up 7.22%) [3] - The Hang Seng Healthcare ETF (513060) rose by 1.04%, reaching a latest price of 0.58 yuan, and has accumulated a 3.21% increase over the past two weeks [3] - The trading volume for the Hang Seng Healthcare ETF was 1.85 billion yuan, with a turnover rate of 2.29% [3] Group 2: Company Earnings - WuXi AppTec announced an expected adjusted net profit of approximately 6.315 billion yuan for the first half of the year, representing a year-on-year growth of about 44.43% [3] - The company anticipates a net profit attributable to shareholders of approximately 8.561 billion yuan, a year-on-year increase of about 101.92%, which includes investment gains from the sale of equity in an associate [3] - The basic earnings per share for WuXi AppTec is projected to be around 3.01 yuan, reflecting a year-on-year growth of approximately 106.16% [3] Group 3: Industry Trends - According to GF Securities, China's innovative drug development has entered a phase of intensive policy support, with significant measures introduced by the National Healthcare Security Administration and the National Health Commission [4] - By the end of 2024, the number of original innovative drugs developed by Chinese companies reached 3,575, surpassing the United States and ranking first globally [4] - Over 30% of global collaborations with upfront payments exceeding 50 million USD in 2024 originated from China, indicating a growing recognition of Chinese innovative drugs by global pharmaceutical giants [4] Group 4: ETF Performance Metrics - The Hang Seng Healthcare ETF has seen a net value increase of 19.11% over the past two years [5] - The ETF's highest monthly return since inception was 28.34%, with an average monthly return of 6.82% [5] - The ETF's Sharpe ratio for the past year was 2.07, indicating strong risk-adjusted returns [5] Group 5: Risk and Valuation - The Hang Seng Healthcare ETF has the lowest relative drawdown of 0.45% compared to its benchmark this year [6] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [6] - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Healthcare Index is 27.75, indicating a valuation below 89.82% of the historical data over the past three years [6]

港股医药股走强，药明康德涨9.52%、药明合联涨7.19%、昭衍新药涨6.78%、基石药业-B涨5.81%。 ...

Group 1 - The core viewpoint of the article highlights the strong performance of Hong Kong pharmaceutical stocks, particularly WuXi AppTec, which saw a rise of 9.52% [1] - Other notable gainers include WuXi Biologics, which increased by 7.19%, Zai Lab, which rose by 6.78%, and Cornerstone Pharmaceuticals, which experienced a growth of 5.81% [1]

Group 1 - The Hong Kong stock market for innovative drugs saw a significant rise in early trading, indicating strong investor interest in the sector [1] - WuXi AppTec (02359.HK) reported a positive earnings forecast, leading to a more than 10% increase in its stock price [1] - WuXi Biologics (02268.HK) experienced a stock price increase of over 7%, reflecting positive market sentiment [1] Group 2 - Other companies in the sector, such as Baoneng Biotech (06955.HK) and Hengrui Medicine (01276.HK), also saw their stock prices rise, indicating a broader trend in the innovative drug market [1]

Group 1 - The Hong Kong stock market's biopharmaceutical sector experienced significant declines in early trading, with Rongchang Biopharmaceutical (09995.HK) dropping over 5% [1] - WuXi AppTec (02268.HK) and WuXi Biologics (02269.HK) both fell by more than 4% [1] - Other companies such as Innovent Biologics (09969.HK) and WuXi AppTec (02359.HK) also saw declines [1] Group 2 - The decline in the biopharmaceutical sector is attributed to the passage of the "Big Beautiful Act" in the U.S., which proposes cuts to healthcare spending [1]

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Market Overview - The Hang Seng Index closed down 0.64% after failing to hold above 24,000 points, despite a temporary boost from financial stocks [1] - U.S. non-farm payrolls increased by 147,000 in June, exceeding expectations of 106,000, leading to a withdrawal of bets on a July interest rate cut by the Federal Reserve [1] - The U.S. government is expected to increase borrowing to offset tax cuts, with corporate tax rates potentially reduced from 21% to around 15% [1] - Market focus is on upcoming tariff deadlines, with President Trump indicating that tariff letters may be sent to trade partners soon [1] Geopolitical Tensions - The conflict between Russia and Ukraine has escalated, with Russia increasing its offensive due to the U.S. reluctance to provide large-scale weaponry to Ukraine [2] Banking Sector - Large funds are consolidating in banks, with Hong Kong's Liyue Group acquiring approximately 199 million shares of Minsheng Bank, raising its stake to 4.945% [3] - Insurance companies are also increasing their stakes in banks, with Ping An Life raising its holdings in China Merchants Bank to 15% [3] - Other banks like Harbin Bank and Zhengzhou Bank are also showing strong trends, with potential for mergers or acquisitions [3] Innovative Pharmaceuticals - Foreign investment in innovative pharmaceuticals is increasing, with Barclays being the largest holder of a new ETF focused on innovative drugs [4] - Companies like Kangfang Biotech and WuXi AppTec have seen significant stock price increases, reflecting strong market confidence in the CXO sector [4] - The Chinese government is taking serious measures to regulate the photovoltaic industry, with potential penalties for below-cost sales [4] Medical Devices and E-commerce - The National Medical Products Administration of China announced support for high-end medical devices based on brain-computer interface technology [5] - Jitu Express has seen a stock price increase due to strong growth projections from TikTok Shop in Southeast Asia [6] Automotive Sector - XPeng Motors launched its new SUV, the XPeng G7, with a lower starting price and immediate availability, although its stock fell by over 6% [6] Alibaba Group - Alibaba announced plans to issue zero-coupon exchangeable bonds worth approximately HKD 12 billion, with a potential impact on its stake in Alibaba Health [6] Fund Distribution in Hong Kong - The Hong Kong Stock Exchange announced the first batch of distributors for its integrated fund platform, which includes 12 Chinese brokers [7] Biopharmaceutical Company Performance - China Biopharmaceutical's new product, a recombinant coagulation factor VIIa, has received approval, contributing to a projected revenue of CNY 28.87 billion and a net profit of CNY 3.5 billion in 2024 [8] - The company is expected to continue its growth trajectory with a strong pipeline of innovative products and approvals [9]

Core Viewpoint - Multiple favorable policies have been released, leading to a collective surge in innovative drug stocks, with Kangfang Biotech's market capitalization surpassing HKD 100 billion [9][11]. Market Performance - On July 4, the Hang Seng Index initially dropped over 1.5% but later narrowed its losses, closing down 0.64% at 23,916.06 points, with a weekly decline of 1.52% [2]. - The total market turnover was HKD 267.8 billion, with southbound funds net buying HKD 6.68 billion [4]. - The healthcare sector index rose by 0.8%, while the materials sector index fell by nearly 1.2% [7]. Stock Highlights - Kangfang Biotech's stock price increased by 9.43% to HKD 116.10, with a total market value reaching HKD 104.2 billion [9][12]. - Other innovative drug companies also saw significant gains, including: - Boan Biotech up 8.55% - Cloudtop New Drug up 4.84% - WuXi AppTec up 4.31% [11][12]. Policy Impact - On July 1, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, which are expected to expand market opportunities and encourage R&D efforts [12][13]. - The introduction of a commercial insurance innovative drug directory is seen as a significant exploration of an innovative payment system, injecting new vitality into the innovative drug ecosystem [13].